Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Internal and Emergency Medicine
Published in: Internal and Emergency Medicine 8/2019

01-11-2019 | Pruritus | CE - Research Letter to the Editor

Randomized trial of two after-dialysis gabapentin regimens for severe uremic pruritus in hemodialysis patients

Authors: Giovanni Maria Rossi, Mattia Corradini, Valentina Blanco, Silvia Mattei, Enrico Fiaccadori, Augusto Vaglio, Lucio Manenti

Published in: Internal and Emergency Medicine | Issue 8/2019

Login to get access

Excerpt

Uremic pruritus (UP) has an overall reported incidence of ~ 46% in patients on hemodialysis, and is a relevant issue in the management of CKD [1, 2]. Gabapentin seems to be the best available treatment option, but since it is mainly eliminated by the kidneys, neurotoxicity is a concern, and sleepiness is the most frequently reported adverse reaction in clinical trials [2]. …
Literature
1.
Schena FP (2011) Management of patients with chronic kidney disease. Intern Emerg Med 6(Suppl 1):77–83CrossRef
2.
Simonsen E, Komenda P, Lerner B et al (2017) Treatment of uremic pruritus: a systematic review. Am J Kidney Dis 70(5):638–655CrossRef
3.
Stander S, Weisshaar E, Mettang T et al (2007) Clinical classification of itch: a position paper of the International Forum for the Study of Itch. Acta Derm Venereol 87(4):291–294CrossRef
4.
Casino FG, Lopez T (1996) The equivalent renal urea clearance: a new parameter to assess dialysis dose. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc Eur Renal Assoc 11(8):1574–1581
5.
Friedman LM, Furberg C, DeMets DL (1998) Fundamentals of clinical trials, 3rd edn. Springer, New YorkCrossRef
6.
Gunal AI, Ozalp G, Yoldas TK, Gunal SY, Kirciman E, Celiker H (2004) Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc Eur Renal Assoc 19(12):3137–3139
7.
Manenti L, Vaglio A, Costantino E et al (2005) Gabapentin in the treatment of uremic itch: an index case and a pilot evaluation. J Nephrol 18(1):86–91PubMed
8.
Naini AE, Harandi AA, Khanbabapour S, Shahidi S, Seirafiyan S, Mohseni M (2007) Gabapentin: a promising drug for the treatment of uremic pruritus. Saudi J Kidney Dis Transpl 18(3):378–381PubMed
9.
Pongcharoen P, Fleischer AB Jr (2016) An evidence-based review of systemic treatments for itch. Eur J Pain 20(1):24–31CrossRef
10.
Collins SL, Moore RA, McQuay HJ (1997) The visual analogue pain intensity scale: what is moderate pain in millimetres? Pain 72(1–2):95–97CrossRef
11.
Pauli-Magnus C, Mikus G, Alscher DM et al (2000) Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. J Am Soc Nephrol 11(3):514–519PubMed
12.
(U.S.) NCI (2009) Common terminology criteria for adverse events (CTCAE). Rev. ed. U.S. Dept. of Health and Human Services, National Institutes of Health, National Cancer Institute, Bethesda
13.
Nofal E, Farag F, Nofal A, Eldesouky F, Alkot R, Abdelkhalik Z (2016) Gabapentin: a promising therapy for uremic pruritus in hemodialysis patients: a randomized-controlled trial and review of literature. J Dermatol Treat 27(6):515–519CrossRef
14.
Solak Y, Biyik Z, Atalay H et al (2012) Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study. Nephrology (Carlton) 17(8):710–717CrossRef
15.
Manenti L, Tansinda P, Vaglio A (2009) Uraemic pruritus: clinical characteristics, pathophysiology and treatment. Drugs 69(3):251–263CrossRef
Metadata
Title
Randomized trial of two after-dialysis gabapentin regimens for severe uremic pruritus in hemodialysis patients
Authors
Giovanni Maria Rossi
Mattia Corradini
Valentina Blanco
Silvia Mattei
Enrico Fiaccadori
Augusto Vaglio
Lucio Manenti
Publication date
01-11-2019
Publisher
Springer International Publishing
Published in
Internal and Emergency Medicine / Issue 8/2019
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-019-02175-4

Other articles of this Issue 8/2019

Internal and Emergency Medicine 8/2019 Go to the issue

IM - ORIGINAL

The effect of management models on thromboembolic and bleeding rates in anticoagulated patients: an ecological study

IM - ORIGINAL

Renal effects of Sacubitril/Valsartan in heart failure with reduced ejection fraction: a real life 1-year follow-up study

IM - REVIEW

Reversal agents for oral anticoagulant-associated major or life-threatening bleeding

IM - COMMENTARY

Left ventricular non-compaction in patients with β-thalassemia: structural remodeling or cardiomyopathy?

IM - REVIEW

Aspirin in primary prevention: the triumph of clinical judgement over complex equations

IM - CASE RECORD

A 29-year-old woman with persistent thrombocytopenia
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits